Changes identified in the expression of biomarkers such as SUMO1 and UCHL1 indicate a phase-dependent nature of the molecular mechanisms accompanying PTSD, highlighting the necessity of an individualized therapeutic approach. The gene discussed is SUMO1; the disease is post-traumatic stress disorder.